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Abstract 
Background: Ertapenem is a broad-spectrum antibiotic that is increasingly being utilized. Its dosing 
convenience renders it suitable for outpatient therapy, and its pharmacokinetic characteristics favour its 
use against complicated urinary tract infections (cUTIs). Despite this, sufficient clinical data are lacking 
for its use against cUTIs in the outpatient setting. We assessed the microbiological and clinical cure rates 
associated with ertapenem treatment for cUTIs in two outpatient parenteral antimicrobial therapy (OPAT) 
departments. Methods: We undertook a prospective observational study of adult patients who received 
ertapenem for cUTIs between August 2010 and August 2014. Data on patient characteristics, clinical 
progress and microbiological results were collected and analysed. Results: Sixty-one patients were 
enrolled. The median age was 59 years (range 24, 83) and 61% were male. The most common diagnoses 
were pyelonephritis (39%) and prostatitis (15%). The most common causative organism was Escherichia 
coli (67%). Extended-spectrum β-lactamase (ESBL)-producing organisms were detected in 72% of 
infections. Microbiological cure was achieved in 67% overall, and was less likely in those with Klebsiella 
pneumoniae infection (OR = 0.21 [95%CI: 0.05 to 0.85] p = 0.029). Clinical cure was observed in 92% of 
patients. Conclusion: In this study of treating cUTIs with ertapenem, we have demonstrated good clinical 
outcomes. A lower than expected microbiological cure rate was observed in those with Klebsiella 
pneumoniae infection. 
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Abstract: Background: Ertapenem is a broad-spectrum antibiotic that is increasingly being
utilised.  Its dosing convenience renders it suitable for outpatient therapy, and its
pharmacokinetic characteristics favor its use against complicated urinary tract
infections (cUTIs). Despite this, sufficient clinical data are lacking for its use against
cUTIs in the outpatient setting. We assessed the microbiologic and clinical cure rates
associated with ertapenem treatment for cUTIs in two outpatient parenteral
antimicrobial therapy (OPAT) departments.
Methods: We undertook a prospective observational study of adult patients who
received ertapenem for cUTIs between August 2010 and August 2014. Data on patient
characteristics, clinical progress, and microbiological results were collected and
analysed.
Results: 61 patients were enrolled. The median age was 59 years (range 24, 83) and
61% were male. The most common diagnoses were pyelonephritis (39%) and
prostatitis (15%). The most common causative organism was Escherichia coli (67%).
ESBL-producing organisms were detected in 72% of infections. Microbiologic cure was
achieved in 67% overall, and was less likely in those with Klebsiella pneumoniae
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infection (OR=0.21 [95%CI: 0.05 to 0.85] p=0.029). Clinical cure was observed in 92%
of patients.
Conclusion: In this study of treating cUTIs with ertapenem, we have demonstrated
good clinical outcomes. A lower than expected microbiologic cure rates was observed
in those with Klebsiella pneumoniae infection.
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ABSTRACT: 3 
Background: Ertapenem is a broad-spectrum antibiotic that is increasingly being utilised.  Its dosing convenience 4 
renders it suitable for outpatient therapy, and its pharmacokinetic characteristics favor its use against complicated 5 
urinary tract infections (cUTIs). Despite this, sufficient clinical data are lacking for its use against cUTIs in the 6 
outpatient setting. We assessed the microbiologic and clinical cure rates associated with ertapenem treatment for 7 
cUTIs in two outpatient parenteral antimicrobial therapy (OPAT) departments.  8 
Methods: We undertook a prospective observational study of adult patients who received ertapenem for cUTIs 9 
between August 2010 and August 2014. Data on patient characteristics, clinical progress, and microbiological 10 
results were collected and analysed.  11 
Results: 61 patients were enrolled. The median age was 59 years (range 24, 83) and 61% were male. The most 12 
common diagnoses were pyelonephritis (39%) and prostatitis (15%). The most common causative organism was 13 
Escherichia coli (67%). ESBL-producing organisms were detected in 72% of infections. Microbiologic cure was 14 
achieved in 67% overall, and was less likely in those with Klebsiella pneumoniae infection (OR=0.21 [95%CI: 15 
0.05 to 0.85] p=0.029). Clinical cure was observed in 92% of patients. 16 
Conclusion: In this study of treating cUTIs with ertapenem, we have demonstrated good clinical outcomes. A 17 
lower than expected microbiologic cure rates was observed in those with Klebsiella pneumoniae infection.  18 
 19 
KEYWORDS: Complicated Urinary Tract Infections; Outpatient Parenteral Antimicrobial Therapy; Ertapenem; 20 
Multi-Drug Resistant Organisms.21 
1. Introduction: 22 
Complicated urinary tract infections (cUTIs) occur in those with a functionally, metabolically, or anatomically 23 
abnormal urinary tract, in addition to catheterised patients[1]. The clinical spectrum ranges from mild cystitis to 24 
life-threatening sepsis. Management of UTIs includes the use of a variety of broad-spectrum antimicrobials[2]. 25 
Recently, emerging resistance mechanisms have rendered common antimicrobial agents less effective. Current 26 
practice recommends 10 to 14 days of therapy with an antimicrobial agent active against a wide range of gram-27 
negative bacilli[2]. With the changing epidemiology of extended-spectrum β-lactamase (ESBL) producing 28 
organisms, the antibiotic options will be increasingly limited, rendering carbapenems as the treatment of choice for 29 
serious infections due to ESBL-producing organisms[3]. 30 
Ertapenem has excellent antimicrobial activity against a broad spectrum of pathogens associated with hospital and 31 
community-acquired infections, including ESBL producing gram negative organisms, which are commonly 32 
implicated in UTIs[4]. It has narrower activity compared with other carbapenems, and has a low minimum 33 
inhibitory concentration (MIC) against ESBL producing organisms rendering it an effective first line agent[5]. 34 
Furthermore, its excretion in the urine gives it a favourable pharmacokinetic profile to treat cUTIs[6]. In a well-35 
designed study, ertapenem was found to be as efficacious as ceftriaxone in treating a cohort of cUTIs with non-36 
ESBL producing gram negatives[7]. 37 
In the outpatient setting, there are few studies on cohorts of patients with cUTIs caused by ESBL producing gram-38 
negative organisms[8-10]. Given that ertapenem can be administered once daily it is suitable for use in outpatient 39 
therapy.  Treating infections in the outpatient setting has been proven cost effective and safe[11]. Hence, we 40 
conducted this study to establish the efficacy of ertapenem in treating cUTIs in the outpatient setting.   41 
2. Methods: 42 
We undertook a prospective, open-label, observational study through two of Singapore’s largest outpatient 43 
parenteral antimicrobial therapy (OPAT) centres over a 4-year period. Eligible patients were those that were 44 
prescribed intravenous (IV) ertapenem 1g, or a renally adjusted dose, every 24 hours as outpatients (either initially 45 
as inpatients or for the full duration). Our study was approved by the Institutional Review Board covering both 46 
hospitals.  47 
Inclusion criteria included non-pregnant adult patients greater than 21 years of age with cUTI as defined by Rubin 48 
et al, [12] due to a pathogen susceptible to ertapenem isolated in urine or blood, and those with favourable clinical 49 
response to initial therapy in hospital, where applicable. Patients with hypersensitivity reactions to ertapenem or in 50 
whom an informed consent could not be obtained were excluded.  51 
As an observational study the investigators had no input into the duration of treatment. Patients were monitored 52 
daily at the OPAT centre. This included clinical assessment for improvement of presenting complaints and 53 
potential adverse events. Serum creatinine, electrolytes and white blood cell count, and urinalysis were performed 54 
routinely or when clinically indicated. Mid-stream urine cultures were performed on the last day of therapy (± 3 55 
days). After completion of treatment, patients were assessed by an infectious diseases physician at 30 days (± 7 56 
days) with repeat urinalysis and mid-stream urine culture.  57 
The primary outcome of the study was microbiological cure, which was defined as a negative culture on any 58 
occasion after treatment. Those with the same organism isolated any time following therapy were considered as 59 
persistent infection, and those who developed a new microorganism were considered as having a superinfection, 60 
regardless of whether they developed symptoms. The secondary outcome of the study was clinical cure defined as 61 
complete resolution of symptoms and signs at diagnosis. Outcome was assessed as therapy success or failure. 62 
Failure was defined as developing adverse outcomes in addition to change of therapy, hospital re-admission due to 63 
cUTI and mortality.  64 
Bacteria were identified by matrix associated laser desorption ionization time of flight mass spectrometry 65 
(MALDI-TOF-MS, Bruker Daltoniks GmHB, Bremen, Germany). Antibiotic susceptibility was determined using 66 
VITEK II (bioMerieux S.A., Marcy l’Etoile, France), and interpreted using breakpoints according to EUCAST..  67 
For descriptive analysis, the means and their standard deviation (SD), or medians with their range were reported. 68 
Chi-square or Fisher’s exact tests were used to compare categorical variables; t-test and Mann–Whitney tests to 69 
compare continuous variables. A multivariate logistic regression model with variables in univariate analysis at a P 70 
< 0.2 level was constructed. Using backward selection, variables were retained in the final logistic regression 71 
model if their significance remained below P = 0.2. All tests were conducted at the 5% level of significance, with 72 
odds ratios (OR) and corresponding 95% confidence intervals (CI) reported.  All statistical analyses were 73 
performed using Stata 9.0 (Stata Corp., College Station, TX, 2005). 74 
3. Results and data analysis: 75 
A total of 61 patients were studied. Baseline demographic features and disease characteristics are summarised in 76 
Table 1. Of the patients 61% were male, and ethnic diversity represented that of Singapore with 62% being of 77 
Chinese ethnicity.  Of all patients 24 (39.3%) had pyelonephritis and 11 (18%) had prostatitis. Six (9.8%) had 78 
associated bacteraemia and were classified as urosepsis, and 20 (32.8%) had a diagnosis of cystitis. The duration 79 
of treatment in the outpatient setting was of a mean of 10 days (SD= +/-7.5). The total duration of therapy 80 
including inpatient and outpatient therapy was of a mean of 22 days (SD= +/-11.8).   81 
Frequently isolated pathogens were Escherichia coli and Klebsiella pneumoniae, recovered from 41 (67.2%) and 82 
14 (23%) respectively. Other cases demonstrated both E.coli and K. pneumoniae (3 patients), Morganella 83 
morganii (2 patients) and 1 had negative cultures (clinical diagnosis as pyelonephritis). All isolates were 84 
susceptible to ertapenem. Out of 60 isolates, 41 (68%) were ESBL producers. Twenty-seven (66%) of the E.coli 85 
isolates and 12 (86%) of the K. pneumoniae isolates were ESBL-positive (Table 2).   86 
Five patients discontinued therapy early, one due to clinical treatment failure, another for persistent symptoms with 87 
additional therapy added and 3 due to adverse reactions. All those completing treatment had a follow up culture 88 
undertaken a median time of 30 days (range: 4-40) after cessation of ertapenem. Forty-one (68%) had 89 
microbiological eradication, 9 (15%) had persistence of the infecting bacteria, and 11 (18%) had a different 90 
organism isolated. Nine out of those 11 had total resolution of symptoms (Table 3). Clinical cure was obtained in 91 
56 (92%) having complete resolution of signs and symptoms. Only 1 (2%) had no improvement in symptoms and 92 
had additional therapy. Three (5%) developed adverse drug reactions attributable to ertapenem.  One stopped 93 
treatment on day 5 of therapy due to rash, but had microbiological eradication and resolution of signs and 94 
symptoms. Two others developed headache and vomiting, and were switched to alternative therapy.   95 
There were 40 (65%) patients who achieved both clinical cure and microbiological eradication, while 9 (15%) had 96 
a clinical cure with a different organism cultured, and 7 (11%) had the same organism isolated but with clinical 97 
cure achieved. Only 2 (3%) were classified as microbiological persistence with clinical failure.  98 
Multivariate logistic regression showed that having an infection with K. pneumoniae at baseline was found to be a 99 
risk factor for not achieving microbiological cure (OR=0.21 [95%CI: 0.05 to 0.85] p=0.029). Compared with other 100 
ethnicities, Indians were more likely to achieve microbiological failure(OR=4.47 [95%CI: 1.06 to 18.9] p= 0.042). 101 
There were no risk factors identified for not achieving clinical cure on univariate analysis, and hence a multivariate 102 
analysis was not conducted. 103 
The mean duration of therapy for those who achieved microbiological cure was 23.6 days (SD=+/- 12.9), and for 104 
those who did not was 17.9 days (SD= +/- 8.4), but the difference was not significant (p=0.08). Similarly, those 105 
achieving clinical cure had a mean duration of therapy of 22.4 days (SD= +/- 12.3), compared with 16.9 days 106 
(SD=+/- 7.2) for those who had no clinical cure (p = 0.219).  ESBL status had no impact on outcomes in our 107 
cohort (microbiological cure p=0.695, clinical cure p=0.663).  108 
4. Discussion 109 
In this study, the safety and efficacy of ertapenem in the OPAT setting were demonstrated for the treatment of 110 
cUTIs. The overall clinical success rate among patients was 92%, while 3 (5%) patients discontinued therapy due 111 
to adverse effects. A total of 52 (85%) had their original organisms eradicated (Table 3). None of the non-ESBL 112 
organisms developed resistance following ertapenem therapy. Patients who had K. pneumoniae infection prior to 113 
commencing therapy were less likely to achieve microbiological eradication. Indeed, the microbiological cure rate 114 
in those with K. pneumoniae was (50%), and significantly contributed to the overall microbiological cure rate 115 
(67%). Of those without microbiological eradication none were re-admitted in the subsequent 3 months for cUTI.  116 
Our study was limited by its observational nature and the relatively small number of participants making subgroup 117 
analysis difficult. Furthermore, it was a single-arm study with no comparator. The study did not look at outcomes 118 
of cUTIs treated by other antimicrobials. Being an OPAT study, there was clearly a selection bias towards patients 119 
who were well enough to continue therapy as outpatients, but the safety and efficacy of ertapenem has been 120 
previously established in the inpatient setting [5, 13-15]. By following well-established microbiological definitions 121 
[12], the study’s primary outcome was microbiological eradication, which may not reflect real life clinical 122 
contexts, where a positive microbiology could indicate colonization rather than infection. This may have reflected 123 
on the relatively prolonged mean duration of therapy, which was not associated with outcome, suggesting that 124 
longer courses were not necessary.  125 
The largest OPAT cohort prior to our study included 50 patients, but it was in a paediatric population[16]. 126 
Similarly, studies conducted in outpatient populations who received ertapenem included even smaller numbers[8-127 
10], with one study including women with simple cystitis. This study demonstrated that ertapenem is a good 128 
alternative to broader-spectrum carbapenems in the treatment of cUTIs. As well as being safe and effective it has 129 
the advantages of a narrower spectrum and lends itself to an OPAT setting being a once daily dosing.  130 
Declarations: 131 
Funding: Supported in part by a research grant from the Investigator Initiated Studies Program of Merck & Co., 132 
Inc. The opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck 133 
& Co., Inc. 134 
Competing interests: None declared 135 
Ethical approval: This study was approved by the National Healthcare Group Domain Specific Review Board 136 
(NHG DSRB)137 
References: 138 
[1]Nicolle LE, Evans G, Laverdieve M, Phillips P, Quan C and Rotstein C. Complicated urinary tract infection in 139 
adults. Can J Infect Dis Med Microbiol. 2005; 16: 349-60. 140 
[2]Hooton TM. Urinary tract infections in adults. N Engl J Med. 2012; 366: 1028-37.  141 
[3]Oteoa J, Perez-Vazquez M and Campos J. Extended-spectrum B-lactamase producing Escherichia coli: 142 
changing epidemiology and clinical impact. Curr Opin Infect Dis. 2010; 23: 320-6. 143 
[4]Mody RM, Erwin DP, Summers AM, Carrero HA, Selby EB, Ewell EB et al. Ertapenem susceptibility of 144 
extended-spectrum beta-lactamase-producing organisms. Ann Clin Microbiol Antimicrob. 2007;6: 6–10. 145 
[5]Fong JJ, Rosé L, and Radigan EA. Clinical outcomes with Ertapenem as a first-line treatment option of 146 
infections caused by extended-spectrum β-lactamase producing Gram-negative bacteria. Ann Pharmacother. 2012; 147 
46: 347-352.  148 
[6] Zhou Jian, Sulaiman Z, Llorin R, Hee Kim-Hor, Lee L, Lye D, Fisher D, Tam V. Pharmacokinetics of 149 
ertapenem in outpatients with complicated urinary tract infections. J Antimicrob Chemother 2014; 69: 2517–2521 150 
[7]Tomera KM, Burdmann EA, Reyna OG, Jiang Q, Wimmer WM, Woods GL et al. Ertapenem versus 151 
ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: 152 
Results of a prospective, randomized, double-blind multicenter study. Antimicrob Agents Chemother. 2002; 46: 153 
2895–2900. 154 
[8]Bazaz R. Champan ALN, and Winstanley TG. Ertapenem administered as outpatient parenteral antibiotic 155 
therapy for urinary tracet infections caused by extended-spectrum-B-lactamase-producing Gram-negative 156 
organisms. J Antimicrob Chemother. 2010; 65: 1510-13. 157 
[9]Song S, Kim C, and Lim D. Clinical efficacy of Ertapenem for recurrent cystitis caused by multi-drug-resistant 158 
extended-spectrum B-lactamase-producing Eschericia coli in female outpatients. Korean J Urol. 2014; 55: 270-159 
275.  160 
[10]Qureshi ZA, Syed A, Doi Y. Safety and efficacy of long-term outpatient ertapenem therapy. Antimicrob 161 
Agents Chemother. 2014; 58: 3437-40. 162 
[11]Fisher DA, Kurup A, Lye D , Tambyah PA , Sulaiman Z, Poon EYH, Lee W, et al. Outpatient parenteral 163 
antibiotic therapy in Singapore. Int J Antimicrob Agents. 2006; 28: 545–550 164 
[12] Rubin RH, Shapiro ED, Andriole VT, Davis RJ, and Stanam WE. General guidelines for the evaluation of 165 
anti-infective drugs for the treatment of urinary tract infection. Clin Infect Dis. 1992; 15 (Supplement 1): S216-166 
S227.  167 
[13]Lye DC, Wijaya L, Chan J, Teng CP, Leo YS. Ertapenem for treatment of extended-spectrum beta-lactamase 168 
producing multidrug-resistant gram-negative bacteraemia. Ann Acad Med Sing. 2008; 37: 831-4. 169 
[14]Wu UI, Chen WC, Yang CS, Wang JL, Hu FC, Chang SC, et al. Ertapenem in the treatment of bacteremia 170 
caused by extended-spectrum beta-lactamase-producing Escherichia coli: a propensity score analysis. Int J Infect 171 
Dis. 2012; 16: e47-e52. 172 
[15]Collins V, Marchalm D, Pogue JM, Moshos J, Bheemreddy S, Sunkara B et al. Efficacy of ertapenem for 173 
treatment of blood stream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae. 174 
Antimicrob Agents Chemother. 2012; 56: 2173-7. 175 
[16]Dalgic N, Saccar M, Bayraktar B, Dincer E, Pelit S. Ertapenem for the treatment of urinary tract infections 176 
caused by extended-spectrum beta-lactamase-producing bacteria in children. Scand J Infect Dis. 2011; 43: 339-177 
343.  178 
 179 
Table 1: Baseline characteristics of patients with cUTIs, (n=61) and their univariate analysis against 












Male (n [%]) 37 (60.7) 70.2 29.7 1.15 0.73-1.83 0.584 
Chinese (n [%]) 38 (62.3) 68.4 31.6 1.17 0.39-3.46 1.0 
Indian (n [%]) 11 (18.0) 45.5 54.5 0.32 0.09-1.23 0.153* 
Malay (n [%]) 7 (11.5) 71.4 28.6 1.25 0.22-7.08 1.0 
Other ethnicity 
(n [%]) 
5 (8.2) 100 0 0.88 0.78-0.98 0.162 
Mean age (+/-
SD) 
59 (+/-16) 59 (+/-15) 61 (+/-17) N/A N/A N/A 
>65 years (n [%]) 35 (57.4) 88.6 11.4 1.17 0.56-2.42 0.651 
K. pneumoniae 
on intitial culture 
(n[%]) 
14 (22.9) 43 57 0.26 0.07-0.89 0.049* 
ESBL detected 41 (67) 75.6 24.4 1.26 0.40-3.93 0.772 
Pyelonephritis (n 
[%]) 
24 (39.3) 75 25 1.83 0.58-5.7 0.405 
Prostatitis (n 
[%]) 
11 (18) 64 36 0.82 0.21-3.22 0.78 
Urosepsis (n 
[%]) 
6 (9.8) 83.3 16.7 2.64 0.29-24.2 0.351 
Cystitis (n [%]) 20 (32.8) 55 45 0.45 0.15-1.37 0.245 
No. of days on 
therapy in OPAT 
(mean +/- SD) 
10 (+/-7.5) 10.5 (+/-7.4) 10.3 (+/-7.9) N/A N/A 0.835 






23.6 (+/-12.9) 17.9 (+/-8.4) N/A N/A 0.08 
* entered into multivariate model 
  180 
Table 2: Microbiological characteristics and outcomes of patients with complicated urinary tract infections 
(n=61). Note: Patients with mixed E.coli and K. pneumoniae (n=3), M. morganii (n=2), and no significant 
growth (n=1) are not included. 
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Table 3: Clinical and microbiological outcomes (n=61) 
 Clinical Cure Clinical Failure Total 
Microbiological cure 40 (65%) 1 (2%) 41 (67%) 
Microbiological 
superinfection* 
9 (15%) 2 (3%) 11 (18%) 
Microbiological 
persistence 
7 (11%) 2 (3%) 9 (15%) 
Total 56 (92%) 5 (8%) 61** 
*Those who had a new micro-organism isolated at the end of therapy or on follow-up, **Including one 
patient with pyelonephritis (no isolated micro-organism at diagnosis) but who had clinical cure and 
clear urine culture following empiric treatment with ertapenem.     
 182 
